

Conventional interferon- α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center

Dan Liu,^{1,2*} Zefeng Xu,^{1,2*} Peihong Zhang,^{1,3} Tiejun Qin,^{1,2} Xiujuan Sun,¹ Shiqiang Qu,^{1,2} Lijuan Pan,^{1,2} Jiao Ma,^{1,3} Wenyu Cai,^{1,3} Jinqin Liu,¹ Huijun Wang,^{1,3} Qi Sun,^{1,3} Zhongxun Shi,^{1,2} Huijun Huang,^{1,2} Gang Huang,⁴ Robert Peter Gale,⁵ Bing Li,^{1,2} Raajit K. Rampal⁶ and Zhijian Xiao^{1,2,3}

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; ²MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; ³Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; ⁴Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ⁵Hematology Section, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK and ⁶Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

*DL and ZX contributed equally as co-first authors.

Correspondence:

BING LI - libing@ihcams.ac.cn

RAAJIT K RAMPAL - rampalr@mskcc.org

ZHIJIAN XIAO - zjxiao@ihcams.ac.cn

doi:10.3324/haematol.2021.280080

Supplementary Figures





Figure S1. The flowchart for patient selection and treatment durations for patients in the IFN and HU cohorts.

The flowchart for patient selection for IFN and HU cohorts. (A). Treatment duration for patients in the IFN (A) and HU (B) cohorts. Each row represents a patient.

*according to the 2016 WHO diagnostic criteria; HU: hydroxyurea; IFN: interferon.

A Clinical features of IFN and HU cohorts matched by age and sex at baseline.

Variables	IFN (n = 67)	HU (n = 67)	p-value
Age, years	53 (48-58)	53 (49-58)	0.855
Gender, female	42 (63%)	42 (63%)	1.000
Palpable splenomegaly	14 (22%)	24 (38%)	0.061
Baseline hemoglobin, g/L	192 (178-209)	197 (186-208)	0.209
Baseline RBC, $\times 10^{12}/L$	7.1 (6.3-7.7)	7.1 (6.4-7.7)	0.658
Baseline HCT, %	59 (55-63)	60 (57-64)	0.169
Baseline WBC, $\times 10^9/L$	12.7 (9.8-15.1)	13.4 (9.7-17.2)	0.427
Baseline PLT, $\times 10^9/L$	453 (344-621)	420 (318-605)	0.676
Baseline <i>JAK2</i> ^{V617F} VAF, %*	57 (41-74)	58 (28-72)	0.420
Abnormal cytogenetics, % (n/N)	4% (2/42)	6% (2/34)	1.000
Thrombosis pre-treatment	22 (34%)	23 (35%)	0.904
Thrombosis risk stratification			0.531
Low risk	38 (59%)	35 (53%)	
High risk	27 (41%)	31 (47%)	
Follow-up from start of treatment, months	52 (35-86)	52(27-90)	0.917




Figure S2. Comparing clinical features and responses between patients in the IFN and HU cohorts matched by age and sex.

Clinical features of the IFN and HU cohorts matched by age and sex at baseline (A). Hematologic responses (A) and molecular responses (B) compared between the IFN and HU cohorts matched by age and sex.

Data are presented as median (IQR) or n (%) in Figure S2A, unless otherwise indicated. IFN: interferon; HU:

hydroxyurea; RBC: red blood cell; WBC: white blood cell; VAF: variant allele frequency; IQR: interquartile range;

* *JAK2*^{V617F} VAF in *JAK2*^{V617F}-mutated patients.






Figure S3. Long-term survival data.

Thrombosis-free survival (A), overall survival (B) and myelofibrosis-free survival (C) are compared between subjects in the conventional IFN and HU cohorts.

TFS: thrombosis-free survival; OS: overall survival; MFS: myelofibrosis-free survival; IFN: interferon; HU: hydroxyurea.